Xeroderma Pigmentosum (XP) is a rare genetic disorder that affects the skin and eyes. It is caused by a genetic mutation that results in an inability to repair damage to the DNA caused by exposure to ultraviolet radiation from the sun. People with XP are at increased risk for developing skin cancer, as well as other types of cancers. XP is an incurable disorder, but early diagnosis and management can help reduce the risk of developing skin cancer. In this article, we will explore the causes, symptoms, diagnosis, and treatment of XP.
Xeroderma Pigmentosum (XP) is a rare genetic disorder that affects the skin and eyes. It is caused by a genetic mutation that results in an inability to repair damage to the DNA caused by exposure to ultraviolet radiation from the sun. People with XP are at increased risk for developing skin cancer, as well as other types of cancers. XP affects both males and females of all ethnicities and is estimated to affect 1 in every 250,000 people.
XP is caused by a mutation in one of eight genes that are responsible for repairing DNA damage caused by ultraviolet radiation. This mutation is inherited in an autosomal recessive manner, meaning that both parents must have a copy of the mutated gene in order for their child to be affected. If only one parent has the mutated gene, the child will be a carrier, but will not be affected by the disorder.
The symptoms of XP vary from person to person, but the most common symptoms are: • Extremely sensitive skin that burns and itches when exposed to the sun • Blistering of the skin when exposed to the sun • Freckling on the face, neck, and arms • Premature aging of the skin • Eye problems such as dry eyes, sensitivity to light, and vision loss • A weakened immune system • An increased risk of developing skin cancer
XP is typically diagnosed through a combination of physical exams, family history, and genetic testing. During a physical exam, a doctor may look for signs of sun damage such as freckling, blistering, and premature aging of the skin. A family history of XP may also be taken into consideration. Genetic testing can confirm a diagnosis of XP, as it can identify the mutation in the genes responsible for repairing DNA damage.
Currently, there is no cure for XP, but there are treatments that can help reduce the risk of developing skin cancer. These treatments include: • Avoiding sun exposure: People with XP should avoid direct sun exposure as much as possible. This includes wearing protective clothing, hats, and sunscreen with SPF 30 or higher. • Phototherapy: Phototherapy is a type of light therapy that can help reduce the risk of skin cancer. It involves exposing the skin to artificial ultraviolet light under the supervision of a doctor. • Topical medications: Topical medications, such as creams and gels, can help reduce the risk of skin cancer. • Surgery: In some cases, surgery may be necessary to remove any cancerous growths.
Xeroderma Pigmentosum (XP) is a rare genetic disorder that affects the skin and eyes. It is caused by a genetic mutation that results in an inability to repair damage to the DNA caused by exposure to ultraviolet radiation from the sun. People with XP are at increased risk for developing skin cancer, as well as other types of cancers. While there is no cure for XP, early diagnosis and management can help reduce the risk of developing skin cancer. Treatment options include avoiding sun exposure, phototherapy, topical medications, and surgery.
1.
Non-Factor Therapies in Hemophilia: Cutting-Edge Approaches to Individualize Care
2.
FDA approves Blenrep for relapsed or refractory multiple myeloma
3.
X-ray and radar technology combined to reduce cancer screening risks
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Researchers discuss HER2-low and HER2-zero in breast cancer
1.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
2.
Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment
3.
The New Era of Oncology: Key Updates and Clinical Insights
4.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
5.
Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
2.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation